TLP
AMRX icon

Tri Locum Partners’s Amneal Pharmaceuticals AMRX Stock Holding History

Tri Locum Partners’s Portfolio AMRX Stock Details AMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-21,622
Closed -$43K – 50
2022
Q4 		$43K Buy
+21,622
New +$48.5K 0.02% 58
2021
Q2 		– Sell
-139,470
Closed -$939K – 31
2021
Q1 		$939K Buy
+139,470
New +$773K 0.23% 34

Other funds holding AMRX

FI
Fosun International Hong Kong, China $446M AUM 13.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return

Tri Locum Partners's AMRX Position: Q1 2023 in Review

Tri Locum Partners sold out of Amneal Pharmaceuticals (AMRX) in Q1 2023, closing a stake of 21,622 shares — an estimated $43K sold.

Tri Locum Partners first reported a position in AMRX in Q1 2021 and held it in 2 quarters. The position peaked at $939K in Q1 2021. 144 funds tracked by Wall St. Rank hold AMRX as of Q1 2023.

  • Tri Locum Partners reported no remaining Amneal Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
  • Tri Locum Partners sold 21,622 Amneal Pharmaceuticals shares in Q1 2023, an estimated $43K.
  • Tri Locum Partners first reported a position in Amneal Pharmaceuticals in Q1 2021 and held it in 2 quarters.
  • Tri Locum Partners's Amneal Pharmaceuticals position peaked at $939K in Q1 2021.
  • 144 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q1 2023.

Based on Tri Locum Partners's 13F filing for Q1 2023, filed 15 May 2023.